(CercleFinance.com) – Valneva announces that it has filed a marketing authorization (MA) application with Health Canada for its single-shot chikungunya vaccine candidate, VLA1553, for people aged 18 and over. more.
This is the second regulatory application for VLA1553 filed by the company, which intends to file more in 2023, including in Europe. A marketing authorization application is currently undergoing priority review by the United States FDA.
VLA1553 is currently the only chikungunya vaccine candidate in the world for which a regulatory review process is underway and could thus become the first vaccine that can address this unmet medical need.